|
| Anadrol 50: |
Anadrol 50 is the very strongest and at the same time, also the most effective oral steroid. The Anadrol 50 compound has an extremely high androgenic effect, which goes hand in hand with an extremely intense anabolic component. For this reason, dramatic gains in strength and muscle mass can be achieved in a very short time. An increase in body weight of 10 - 15 pounds or more in only 14 days is not un-usual.
By the use of Anadrol 50, water retention is considerable, so that the muscle diameter quickly increases and the user gets a massive appearance within record time. Since the muscle cell draws a lot of water, the entire muscle system of most athletes looks smooth, in part even puffy. Anadrol does not cause a qualitative muscle gain but rather a quantitative one, which in the off-season is quite welcome.
Anadrol "lubricates" the joints since water is stored there as well. On the one hand this is a factor in the enormous increase of strength and, on the other hand, it allows athletes with joint problems a painless workout. Power lifters in the higher weight classes are sold on Anadrol. A strict diet, together with the simultaneous intake of Nolvadex and Proviron, can significantly reduce water retention so that a distinct increase in the solid muscles is possible.
By taking Anadrol the athlete experiences an enormous "pump effect" during the workout in the exercised muscles. The blood volume in the body is significantly elevated causing a higher blood supply to the muscles during workout. Anadrol increases the number of red blood cells, allowing the muscle to absorb more oxygen. The muscle thus has a higher endurance and performance level.
The highly androgenic effect of Anadrol stimulates the regeneration of the body so that the often-feared "over-training" is unlikely. Anadrol helps more than any other steroid during dieting to maintain the muscle mass and to allow an intense workout. Many bodybuilders therefore use it up to about one week before a competition, solving the problem of water retention by taking anti-estrogens and diuretics so that they will appear bulky and hard when in the limelight. |
|
Like methandrostenolone (Dianabol), oxymetholone ( anadrol ) does not bind well to the androgen receptor (AR), and most of the anabolism it provides is via non-AR-mediated effects. It is therefore a Class II steroid and is best stacked with a Class I steroid. The drug appears to give the same benefits as Dianabol. Unlike Dianabol, however, it seems that anadrol is progestagenic. It has been observed to cause nipple soreness or to aggravate gynecomastia even in the presence of high dose antiestrogens, strongly suggesting that the effect is not estrogenic. That effect can be reduced by concurrent use of stanozolol (Winstrol), which is anti-progestagenic. This progestagenic effect of oxymetholone is only a concern when using aromatizing steroids. With androgens such as Primobolan, anadrol stacks very nicely and is a surprisingly friendly drug. In contrast, with testosterone it is a very harsh drug.
Oxymetholone does not convert to estrogen, and thus antiestrogens are not required if no aromatizable AAS are being used. However, in concert with aromatizing drugs, oxymetholone is notorious for worsening "estrogenic" symptoms, possibly by producing progestagenic symptoms which the bodybuilder confuses as estrogenic, or by altering estrogen metabolism, or by upregulating aromatase.
Compared to what bodybuilders expect of it, the drug is reasonably mild when no aromatizing steroids are present. I consider its potency approximately comparable to Dianabol. It is not unusual for a first time user to do quite well on an oxymetholone-only cycle, but more advanced users will want to stack with another steroid. Typical use is 50-150 mg/day, which should be divided into several doses per day.
Because oxymetholone is 17-alkylated, it is stressful to the liver. It is better to limit use to no more than 6 weeks or preferably four weeks before taking a break of at least equal length. Many users feel that it is more effectively used in the beginning parts of the cycle, rather than in the last few weeks.
Trivial name
Oxymetholone ( Anadrol )
Systematic name
5-alpha,17-beta-Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-
CAS number
434-07-1
ATC code
A14AA05
Merck Index Number
7036
Chemical formula
C21H32O3
Molecular weight
332.477 g/mol
Bioavailability
95%
Metabolism
Hepatic
Elimination half-life
9 hours
Excretion
Urinary: 95%
Pregnancy category
X
Legal status
Prescription only (US)
Controlled substance
Yes, DEA Schedule III (US)
Routes of administration
Oral |
| |
| Teva Announces the Appointment of Dr. Philip Frost As Chairman of Its Board of DirectorsJerusalem, Israel, March 9, 2010 -
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today
that its Board of Directors received a letter from Mr. Eli Hurvitz
indicating that he wishes to be released from his duties at Teva in
order to...


PhRMA Statement About Accessing Online Health InformationWashington, D.C. (March 9, 2010) —
Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President David E. Wheadon
issued the following statement regarding patients’ access to
reliable health information...


Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory DiseaseCollaboration Exploits Cellzome's World-Leading Proteomics
Technology in Epigenetics
CAMBRIDGE, England and HEIDELBERG, Germany, March 10,
2010/PRNewswire/ -- Cellzome today announced that it has formed a
second strategic alliance with...


Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet BiotechProvides Promising Biologic Intended to Treat Multiple
Sclerosis and Compounds that Complement Abbott's Existing Diverse
Oncology Program
ABBOTT PARK, Ill. and REDWOOD CITY, Calif., March 9
/PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) and Facet...


Catalina Marketing Hires Johnson & Johnson Executive to Lead Health Care Services DivisionST. PETERSBURG, FL. March 9, 2010– Catalina Marketing
Corporation, the global leader in precision marketing and
shopper-driven media, today announced the appointment of Renee
Selman as President of its health care division, Catalina...


GSK CEO Andrew Witty Dedicates albendazole Facility in Nashik to WHO?s Global Programme to Eliminate LFLONDON, March 8, 2010--GlaxoSmithKline (GSK) CEO Andrew
Witty today dedicated a new production facility at its Nashik site
in India to the manufacture of albendazole, part of a combination
treatment used within the World Health...


Cardiff University and Merck Serono Launch International Survey For Couples Trying To Conceive• Largest study aimed at understanding the fertility
decision-making process of today’s couples trying to conceive
• Survey available in twelve languages on www.startingfamilies.com
Mumbai, India, March 9, 2010 – Merck Serono, a...


Exelixis Announces Restructuring- Aligning Resources with Late-Stage Compounds XL184,
XL147 and XL765 -
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 8, 2010 -
Exelixis, Inc. (Nasdaq:EXEL) today announced a restructuring as a
consequence of its continued strategy to focus...


Nabi Closes License Deal With GlaxosmithklineFrom Associated Press (March 8, 2010)
ROCKVILLE, Md. -- Nabi Pharmaceuticals said Monday it closed an
option and license agreement for the smoking vaccine candidate
NicVAx with GlaxoSmithKline.
The deal is potentially worth more than $500 million,...


Mylan Rebukes and Cites Flaws in Bayer-Sponsored Mylan-Nifedipine Extended Release Bioequivalence Study in CanadaTORONTO, March 9 /CNW Telbec/ - Mylan (Nasdaq: MYL) today
reported that it has identified multiple flaws within a purported
bioequivalence study sponsored by Bayer Inc. of Canada. The study
compared Bayer's antihypertensive Adalat(R) XL(R) tablets,...


Roche Suspends Arthritis Drug Study After DeathsFrom Associated Press (March 8,
2010)
BASEL, Switzerland -- Swiss
pharmaceutical company Roche Group
said Monday it has suspended a late-stage trial for a new
rheumatoid arthritis and lupus drug after several patients died
from...


Roche and Biogen Idec Decide to Suspend Ocrelizumab Treatment - Rheumatoid Arthritis Development Programme on HoldFuture of the Ocrelizumab RA clinical programme under
evaluation
Basel, Switzerland, March 8, 2010--Roche
and Biogen Idec announced
today their decision to suspend Ocrelizumab
treatment of patients in the Rheumatoid Arthritis
(RA)...


Isis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9RxCARLSBAD, Calif., March 8, 2010
/PRNewswire via COMTEX/ -- Isis
Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has
earned a $6 million milestone payment from
Bristol-Myers Squibb Company (NYSE: BMY)
related to the acceptance of...


XenoPort Restructures to Focus on Key ProgramsSANTA CLARA, Calif.--(BUSINESS WIRE)--Mar 5, 2010 - XenoPort,
Inc. (Nasdaq:XNPT) announced today a restructuring that includes an
overall reduction in its workforce of approximately 50%. The
restructuring is designed to focus the Company's resources...


La Jolla Pharmaceutical Announces Termination of Merger Agreement with Adamis PharmaceuticalsSAN DIEGO--(BUSINESS WIRE)--Mar 5, 2010 - La Jolla
Pharmaceutical Company (Pink Sheets: LJPC) today announced that La
Jolla and Adamis Pharmaceuticals Corporation (OTCBB: ADMP) have
agreed to terminate their merger agreement relating to the...


Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.LITTLETON, Colo., March 4 /PRNewswire-FirstCall/ -- Chay
Enterprises, Inc. (OTC:CHYE) (BULLETIN BOARD: CHYE) is pleased to
announce today that the company has merged with DMI Life Sciences,
Inc to form Ampio Pharmaceuticals, Inc. Ampio...


Pfizer CEO Gets 12.5 Percent Raise From Last Year's $14.9MPfizer CEO Gets 12.5 Percent Raise From Last Year's $14.9M [The
Day, New London, Conn.]
From Day, The (New London, CT) (March 4, 2010)
Mar. 4--As Pfizer Inc. continues a series of layoffs that are
expected to total nearly 20,000 by the time its...


Pfizer, Bristol-Myers Say Clot Drug Meets GoalsFrom Associated Press (March 5, 2010)
NEW YORK -- Bristol-Myers Squibb Co. and Pfizer Inc. on Thursday
said their blood thinner apixaban was more effective than
Sanofi-Aventis’ Lovenox in a late stage clinical trial.
The study compared the...


Grassley Statement on GAO Report about FDA Office of Criminal InvestigationsM E M O R A N D U M
TO: Reporters and Editors
RE: FDA Criminal Division
DA: Thursday, March 4, 2010
Senator Chuck Grassley issued the comment below about a newly
released report of the Government Accountability Office regarding
the criminal division...


Abbott Executives To Chair Medical Device LobbyFrom Associated Press (March 4, 2010)
WASHINGTON -- The medical device industry’s chief advocacy
group, AdvaMed, said Thursday an Abbott Laboratories executive will
serve as its chairman.
James Mazzo is President of Abbott Medical Optics, a...


Unilife and sanofi-aventis Agree to Exclusivity List for Unifill Ready-to-Fill Syringe
LEWISBERRY, Pa., March 2 /PRNewswire-FirstCall/ -- Unilife
Corporation ("Unilife" or "Company") (NASDAQ:UNIS) , today announced that it has
agreed to a list of therapeutic drug classes ("Exclusivity List")
within which sanofi-aventis...


Merck Statement on Vioxx Judgment in AustraliaWHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Mar 5, 2010 - Today,
the Federal Court in Australia published its judgment in the
Peterson case. The Court found against MSD Australia on two claims
under Australian statutory provisions. The Court...


District Court Upholds FDA's Grant of 5-Year Market Exclusivity to VYVANSE(R)PHILADELPHIA, March 4, 2010/PRNewswire-FirstCall/ -- Shire plc
(LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical
company, announces that the United States District Court for the
District of Columbia ("Court"), following extensive...


H. Lundbeck A/S (DK) - Fourth Quarter and Full Year Report 2009 - Lundbeck Delivers 22 Percent Revenue Growth for 2009 and Meets Financial Expectations for 2009COPENHAGEN, March 4, 2010--H. Lundbeck A/S
(Lundbeck) announces 2009 results, which meet financial forecasts
and continue to show growth in all regions. Full year revenue
was DKK 13,747 million and increased 22% at
constant exchange rates compared...


NICE Appraisal of azacitidine for Myelodysplastic SyndromesLONDON, March 4, 2010--The National Institute for Health and
Clinical Excellence (NICE) is currently appraising the use of
azacitidine (Vidaza, Celgene) for myelodysplastic syndromes. In the
final draft guidance, published today (4 March 2010), NICE...


Bristol-Myers Squibb to Highlight Strong Pipeline and Execution of BioPharma Strategy in Meeting with Investment CommunityWell-Positioned to Deliver
in 2010 and On Track to Execute BioPharma Strategy
Provides 2013 Minimum
Non-GAAP EPS Guidance
Will Present In-Depth
Review of Robust, Differentiated Pipeline
NEW YORK--(BUSINESS WIRE)--Mar 4, 2010 - During a meeting...


KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs
Judge Sentences St. Louis-Based Company to Pay $27.6 Million
in Fines, Restitution and Forfeitures
WASHINGTON, March 2 /PRNewswire-USNewswire/ -- Ethex
Corporation, a wholly owned subsidiary of St. Louis-based drug
manufacturer, KV...


Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' Crinone Progesterone Gel Product Line- Established, patient-preferred infertility treatment - -
Expands Watson's Women's Health brand product portfolio - - Preterm
birth clinical trials currently underway - - Company acquires 11.2
million shares of Columbia common stock -
MORRISTOWN,...


Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone FranchiseWatson to acquire rights to
CRINONE® and
PROCHIEVE® and 11.2 million shares of
common stock for upfront and milestone payments of up to $92.5
million plus royalties
Also announces contingent agreements to retire
debt
Investor conference call...


Danish Lundbeck to Launch Two Depression Drugs in Phase IIIFrom Nordic Business Report (March 3, 2010)
3 March 2010 - Danish pharma company H Lundbeck
A/S (CPH: LUN) and its R&D partner Japanese
TakedaPharmaceutical Company Ltd (TYO:
4502) said today they will start pivotal clinical phase III...


Bristol-Myers Squibb and Allergan Enter Global Agreement on Investigational Neuropathic Pain MedicinePRINCETON, N.J. & IRVINE, Calif.--(BUSINESS WIRE)--Mar 3,
2010 - Bristol-Myers Squibb Company (NYSE:
BMY) and Allergan
, Inc. (NYSE: AGN) today announced a global
agreement for the development and commercialization of
AGN-209323, a Phase...


Lundbeck and Takeda Finalize Plans to Initiate Phase III Pivotal Clinical Trials with Lu AA21004 and Lu AA24530OSAKA, March 3, 2010--H. Lundbeck A/S (Lundbeck) and Takeda
Pharmaceutical Company Limited (Takeda) today jointly announced the
plans for the additional clinical phase III studies on Lu AA21004
and phase III studies on Lu AA24530 in patients with...


Teva Announces Favorable Court Ruling in Generic Hyzaar and Cozaar LitigationJERUSALEM--(BUSINESS WIRE)--Mar 2, 2010 - Teva Pharmaceutical
Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Court
of Appeals for the District of Columbia Circuit has ruled in Teva's
favor by overturning a July 31, 2009, district court...


FDA Grants Final Approval For Generic FlomaxFrom Associated Press (March 2, 2010)
HAYWARD, Calif. -- Drugmaker Impax Laboratories Inc. said
Tuesday the Food and Drug Administration gave final approval to its
generic version of the enlarged prostate treatment Flomax.
Impax plans to start...


Dendreon Rises; FDA Says No Meeting on ProvengeFrom Associated Press (March 2, 2010)
WASHINGTON -- Shares of biotechnology company Dendreon Corp.
jumped Tuesday after federal regulators said they don’t plan
to hold a public meeting on the company’s prostate cancer
treatment, possibly...


Nabi Shareholders Approve Deal With GlaxoFrom Associated Press (March 2, 2010)
ROCKVILLE, Md. -- Nabi Biopharmaceuticals said Tuesday
shareholders approved its option and license agreement for the
smoking vaccine candidate NicVAx with GlaxoSmithKline.
More than 73 percent of Nabi’s...


Bristol-Myers Squibb Names Lamberto Andreotti CEO, Effective May 4; James Cornelius to Retire as CEO, Remain as ChairmanNEW YORK--(BUSINESS WIRE)--Mar 2, 2010 -
Bristol-Myers Squibb Company (NYSE:BMY) today announced that
Lamberto Andreotti, 59, has been designated by the Board of
Directors to serve as the company's chief executive officer,
effective May 4, when...


Abbott and Enanta Announce Advancement of Hepatitis C CollaborationInitiation of Phase 2 Clinical Trial Investigating Three
Individual HCV Antivirals
ABBOTT PARK, Ill. and WATERTOWN, Mass., March 2
/PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) and Enanta Pharmaceuticals announced
today the advancement of their...


Med Ad News' 21st Annual Manny Awards Will Honor Healthcare Advertising AgenciesMED AD NEWS' 21ST ANNUAL MANNY AWARDS WILL HONOR HEALTHCARE
ADVERTISING AGENCIES
NEWTOWN, Pa., March 2, 2010 - - On Thursday, April 22,
2010, Med Ad News magazine will host its 21st Annual Manny Awards
celebrating creative excellence in...


Baxter to Acquire All Outstanding Equity of ApaTech, Including ACTIFUSEDEERFIELD, Ill. and LONDON, U.K., March 1, 2010 – Baxter
International Inc. (NYSE:BAX), a global, diversified healthcare
company, and ApaTech, a private equity-backed, U.K.-based
orthobiologic products company, today announced a...


|
|
|
|
|